Loss of MiR-155 Sensitizes FLT3-ITD<sup>+</sup>AML to Chemotherapy and FLT3 Inhibitors via Glycolysis Blocking by Targeting PIK3R1
Lingyan Wang(Zhejiang Chinese Medical University), Jianda Hu(Fujian Medical University)
Cited by 6
Related Papers
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia
|Proceedings of the National Academy of Sciences|2017|148
Discovery of Cyclic Acylguanidines as Highly Potent and Selective β-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part I—Inhibitor Design and Validation
|Journal of Medicinal Chemistry|2009|121
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
|Journal of Hematology & Oncology|2020|50